Combination immunotherapy and targeted therapy for advanced liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy pill (regorafenib) for people with advanced liver cancer that has progressed after first-line treatment. The goal is to see if this combination can shrink tumors or slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced liver cancer (hepatocellular carcinoma) that cannot be removed with surgery.
- Your cancer has grown or you couldn't tolerate your first treatment.
- You have at least one tumor that can be measured on a scan.
- You are generally able to care for yourself (ECOG score 0-1).
- Your liver function is good (Child-Pugh class A).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of three drugs—TUDCA (a bile acid supplement), camrelizumab (an immunotherapy), and regorafenib (a targeted therapy)—for people with advanced liver cancer that has continued to grow after earlier immunotherapy plus Avastin treatment. The goal is to see if this new mix can help stop the cancer from growing.
This trial tests a new combination of two immunotherapy drugs plus a targeted therapy and a procedure called TACE (which blocks the blood supply to the tumor) for people with advanced liver cancer. It aims to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of two immunotherapy drugs, TACE (a procedure to block blood flow to tumors), and lenvatinib (a targeted therapy) for people with liver cancer that has not responded to initial treatment. It aims to see if this combination can help shrink tumors or slow cancer growth.
This trial tests whether combining two medicines (trastuzumab and regorafenib) works better than regorafenib alone for people with advanced liver cancer that has progressed after first-line treatment. It aims to see if the combination helps control the cancer longer.
This trial tests a combination of immunotherapy drugs, radiation therapy, and a targeted therapy drug before and after surgery for people with intermediate-stage liver cancer that can be surgically removed. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus bevacizumab (a drug that cuts off blood supply to the tumor) given after surgery or ablation for liver cancer. The goal is to lower the chance of cancer coming back. The treatment is given as an infusion and may help patients with certain high-risk features.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.